Therefore, blockade of overactivated cancer pathways can be an important target for cancer therapy.30, 31 For instance, tyrosine kinase inhibitors have been successfully used to treat mutant EGFR non‐small cell lung cancer. The gene discussed is EGFR; the disease is lung cancer.